Storia in 2 fonti

Updated: Odyssey CEO talks about $279M IPO and building a 'permanent' biotech

Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mesi fa

Updated: Odyssey CEO talks about $279M IPO and building a 'permanent' biotech

Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday.

originale

biopharmadive.com1 mesi fa

Odyssey, on second try, snags $279M in an IPO

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concurrent private deal.

Leggi questa versione → originale

Timeline cronologica

giovedì 7 maggio 2026·biopharmadive.com
Odyssey, on second try, snags $279M in an IPO
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even…
venerdì 8 maggio 2026·endpoints.news
Updated: Odyssey CEO talks about $279M IPO and building a 'permanent' biotech
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday.